We invite you to be part of this journey and hope you will join us.
Interested to be part of this meeting focusing on translating new data into clinical decisions for everyday practice in renal, bladder and/or prostate cancer? Contact us directly (luc.vanruysevelt@e-hims.com) or complete the contact form hereunder to download the sponsorship guide.
The Journey benefits
-
Are you planning a key presentation at a major congress or expecting a ground-breaking publication during 2026?
-
We translate your highlight into a clinical case, send it out to the specialists community and provide you with a report on the outcomes.
-
A RENALC-BLADDR-PROSCA faculty member will also provide his opinion on your case.
The Destination benefits
-
Your case will be discussed at the multidisciplinary and international RENALC-BLADDR-PROSCA.
-
Onsite exhibition space.
Compliance
EthicalMedTech
RENALC-BLADDR-PROSCA 2026 have been reviewed by the MedTech Europe Codeof Ethical Business Practice.
RENALC 2026 (EMT-26-09785), BLADDR 2026 (EMT-26-09787) and PROSCA 2026 (EMT-26-09786) have been determined as compliant with MedTech Europe Code ofEthical Business Practice and EFPIA Code of Practice.
More info: ethicalmedtech.eu